CA2812750C — Dual inhibitors of met and vegf for the treatment of castration-resistant prostate cancer and osteoblastic bone metastases
Assigned to Exelixis Inc · Expires 2020-10-06 · 6y expired
What this patent protects
A compound for use in treating castration resistant prostate cancer (CRPC), or osteoblastic bone metastases associated with CRPC, the compound being of Formula I: or a pharmaceutically acceptable salt thereof, wherein: R1 is halo; R2 is halo; R3 is (C1-C6)alkyl; R4 is (C1-C6)a…
USPTO Abstract
A compound for use in treating castration resistant prostate cancer (CRPC), or osteoblastic bone metastases associated with CRPC, the compound being of Formula I: or a pharmaceutically acceptable salt thereof, wherein: R1 is halo; R2 is halo; R3 is (C1-C6)alkyl; R4 is (C1-C6)alkyl; and Q is CH or N.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.